Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Microcap Kitchen Canadian Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Hodor who wrote (24536)	5/30/2014 2:05:31 PM
From: Hodor	Respond to of 49402

Oh I forgot to include the most recent mention of TLT I found: 321gold.com I like this part the best "Need I remind our readers how valuable a vaccine to cure a cancer would be?" I am sure he is getting paid by them in some way (they always are) but I still agree with what he says.

To: Hodor who wrote (24536)	5/30/2014 2:11:05 PM
From: Acton	Read Replies (1) \| Respond to of 49402

Fair points. Perhaps it just needs to cool off before it can push any higher. A lot of volume transpiring the last couple of days (approx. 25 million shares have exchanged hands) so it is difficult to tell if it is fast short term money getting in and then out or if it is some positioning by larger houses. Keep in mind that I have done zero dd on the share structure of the company - only basing my view on the last 2 days of action.

To: Hodor who wrote (24536)	5/30/2014 9:01:21 PM
From: ogi	2 Recommendations Recommended By ayeyou Hodor Read Replies (1) \| Respond to of 49402

I too am taking a longer term view of TLT, not trying to trade this breakout but would consider adding on a deeper retrace, in at avg 25. Current burn rate not too high, assume much of current activity will result in warrant exercise and more cash to the til. TLT on record saying they will need another PP before launching first human trials, 2015. now the warrant cash should allow them the flexibility to undertake another PP without undue pricing pressure. Meanwhile, I think it worth noting that TLT's destruction of cancer cell nucleus is unlike most pharmaceutical approaches to attacking cancer. Therefore I believe a much higher chance the rodent model can be replicated in humans. Lots of successes in mice models across biotech that do not replicate in humans due to complexity of differences in biochemistry. But in this instance a dead nucleus is a dead nucleus so long odds vastly improved with or without the newly observed memory function revealed yesterday.